Buy Febuxostat Powder Drug Treat Chronic Gout and Hyperuricemia Online
Febuxostat Specification
Product Name: Febuxostat
CAS: 144060-53-7
Natural/Synthetic: Synthetic
Extraction source: A crystal form
Level: Pharmaceutical grade
Content: 99%
Appearance: white powder
Packing: 1KG/aluminum foil bag
Ingredients: 2-[3-Cyano-4-isobutoxyphenyl]-4-methylthiazole-5-carboxylic acid
Physical and chemical properties: white or almost white powder; no smell, no taste. This product is dissolved in acetonitrile, acetone, methanol
Category: Pharmaceutical Raw Materials
Industry: Pharmaceuticals
Field: Anti gout drugs
Deferred products: febuxostat tablets, capsules
Application: Chronic hyperuricemia for the treatment of gout
Usage and dosage: once a day, 80mg once, and take it with food. After 2 to 4 weeks of treatment, if the serum uric acid value is higher than 6 mg/dL (357 μmol/L), increase the dose to 120 mg/day.
Febuxostat Certificate of Analysis
| Product name |
Febuxostat |
| CAS No. |
144060-53-7 |
Outer Packing |
Foil bag |
| Production date |
2018.2.10 |
Shelf life |
2020.2.9 |
| Standard adopted |
Enterprise Standard |
| Items of analysis |
Specification |
Results |
| Appearance |
White to almost white crystalline powder, odorless |
White crystalline powder, odorless |
| Solubility |
Easily soluble in N,N-Dimethylformamide, soluble in Dimethyl sulfoxide. Sparingly soluble in Chloroform.Sligt soluble in methanol, practically insoluble in water |
Conforms |
| m.p. |
207℃~211℃ |
207.5℃~208.5℃ |
| Identification |
Conforms |
Conforms |
| ImpurityⅠ |
NMT0.1% |
N.D. |
| ImpurityⅡ |
NMT0.1% |
N.D. |
| ImpurityⅢ |
NMT0.1% |
N.D. |
| ImpurityⅣ |
NMT0.1% |
0.02% |
| Water |
≤2.0% |
0.5% |
| Residue on ignition |
≤0.1% |
0.02% |
| Heavy metals |
≤20ppm |
Conforms |
| Ethanol |
≤5000ppm |
23ppm |
| Tetrahydrofuran |
≤720ppm |
N.D. |
| N-hexane |
≤290ppm |
N.D. |
| N,N-Dimethylformamide |
≤880ppm |
N.D. |
| Dichloromethane |
≤600ppm |
24ppm |
| Assay |
98.0%~102.0%（Calculated as anhydrous basis） |
99.2% |
| Solubility |
Easily soluble in N,N-Dimethylformamide, soluble in Dimethyl sulfoxide. Sparingly soluble in Chloroform.Sligt soluble in methanol, practically insoluble in water |
Conforms |
| m.p. |
207℃~211℃ |
207.5℃~208.5℃ |
| Identification |
Conforms |
Conforms |
| ImpurityⅠ |
NMT0.1% |
N.D. |
| ImpurityⅡ |
NMT0.1% |
N.D. |
| ImpurityⅢ |
NMT0.1% |
N.D. |
| ImpurityⅣ |
NMT0.1% |
0.02% |
| Water |
≤2.0% |
0.5% |
| Residue on ignition |
≤0.1% |
0.02% |
| Heavy metals |
≤20ppm |
Conforms |
| Ethanol |
≤5000ppm |
23ppm |
| Tetrahydrofuran |
≤720ppm |
N.D. |
| N-hexane |
≤290ppm |
N.D. |
| N,N-Dimethylformamide |
≤880ppm |
N.D. |
| Dichloromethane |
≤600ppm |
24ppm |
| Assay |
98.0%~102.0%（Calculated as anhydrous basis） |
99.2% |
| Conclusion |
Qualified |
Febuxostat Common Side effects
The adverse effects associated with febuxostat therapy include nausea, diarrhea, arthralgia, headache, increased hepatic serum enzyme levels and rash.
